In this study, we devised and applied a virtual screening campaign on a large library of commercially available compounds, searching for molecules endowed with Hsp90/HDAC6 dual activity and antiproliferative activity against LNCaP and PC-3 prostate cancer cells. This evidence concerns the gene HSP90AA1 and prostate carcinoma.